Feature

Cardiovascular disease in oncology


 

In the first quarter of 2015, a number of papers that addressed cardiovascular issues in oncology were published. These included studies of the cardiovascular toxicity of cancer therapy, treatment guidelines from the American Society of Clinical Oncology (ASCO) for venous thromboembolism prophylaxis (VTE), and the prognostic significance of superficial vein thrombosis.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Additive radiotherapy’s advantages outweigh QOL disadvantages
MDedge Hematology and Oncology
VIDEO: Genomic biomarker predicts pembrolizumab response
MDedge Hematology and Oncology
VIDEO: More aggressive treatment with docetaxel boosts survival in prostate cancer
MDedge Hematology and Oncology
VIDEO: Dr. Walter M. Stadler gives take-home messages from ASCO 2015 GU sessions
MDedge Hematology and Oncology
ASCO: Research IDs new subtype of refractory prostate cancer
MDedge Hematology and Oncology
ASCO: Two hits and a miss against advanced urothelial cancer
MDedge Hematology and Oncology
Prostate cancer screening for men over 50 has declined
MDedge Hematology and Oncology
AUA: Renal mass biopsy trend tied to nonsurgical RCC treatment
MDedge Hematology and Oncology
Urine assay ruled out high-grade prostate cancer
MDedge Hematology and Oncology
Isolated splenic metastasis in a patient with two distinct genitourinary malignancies
MDedge Hematology and Oncology